Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more
Anavex Life Sciences Corp (AVXL) - Net Assets
Latest net assets as of December 2025: $126.62 Million USD
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) has net assets worth $126.62 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($132.99 Million) and total liabilities ($6.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $126.62 Million |
| % of Total Assets | 95.21% |
| Annual Growth Rate | 47.89% |
| 5-Year Change | -37.1% |
| 10-Year Change | 1403.91% |
| Growth Volatility | 1805.88 |
Anavex Life Sciences Corp - Net Assets Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual net assets of Anavex Life Sciences Corp from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $94.87 Million | -21.12% |
| 2024-09-30 | $120.26 Million | -15.22% |
| 2023-09-30 | $141.85 Million | -0.45% |
| 2022-09-30 | $142.49 Million | -5.52% |
| 2021-09-30 | $150.82 Million | +453.73% |
| 2020-09-30 | $27.24 Million | +34.24% |
| 2019-09-30 | $20.29 Million | -0.98% |
| 2018-09-30 | $20.49 Million | -15.51% |
| 2017-09-30 | $24.25 Million | +284.49% |
| 2016-09-30 | $6.31 Million | -50.75% |
| 2015-09-30 | $12.81 Million | +6549.68% |
| 2014-09-30 | $192.63K | +107.82% |
| 2013-09-30 | $-2.46 Million | +14.33% |
| 2012-09-30 | $-2.88 Million | -151.68% |
| 2011-09-30 | $-1.14 Million | +61.41% |
| 2010-09-30 | $-2.96 Million | +23.27% |
| 2009-09-30 | $-3.86 Million | -68.30% |
| 2008-09-30 | $-2.29 Million | -395.60% |
| 2007-09-30 | $-462.50K | -2881.78% |
| 2006-09-30 | $-15.51K | +40.39% |
| 2005-09-30 | $-26.02K | -201.62% |
| 2004-09-30 | $25.61K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anavex Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38243360500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $87.00K | 0.09% |
| Other Components | $477.23 Million | 503.04% |
| Total Equity | $94.87 Million | 100.00% |
Anavex Life Sciences Corp Competitors by Market Cap
The table below lists competitors of Anavex Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intrum Justitia AB
ST:INTRUM
|
$408.59 Million |
|
CBOAF
PINK:CBOAF
|
$408.63 Million |
|
Shutterstock
NYSE:SSTK
|
$408.77 Million |
|
HEALTHCARE TR.PFD SH DL25
F:4ON
|
$408.87 Million |
|
Il Dong Pharmaceutical Co Ltd
KO:249420
|
$408.45 Million |
|
Xiamen Insight Investment Co Ltd
SHE:000526
|
$408.37 Million |
|
Groupe Gorgé SA
PINK:GGRGF
|
$408.35 Million |
|
Evergreen International Storage & Transport Corp
TW:2607
|
$408.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anavex Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 120,263,000 to 94,869,000, a change of -25,394,000 (-21.1%).
- Net loss of 46,377,000 reduced equity.
- New share issuances of 9,198,000 increased equity.
- Other factors increased equity by 11,785,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.38 Million | -48.89% |
| Share Issuances | $9.20 Million | +9.7% |
| Other Changes | $11.79 Million | +12.42% |
| Total Change | $- | -21.12% |
Book Value vs Market Value Analysis
This analysis compares Anavex Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 339.82x to 4.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-09-30 | $0.01 | $4.55 | x |
| 2005-09-30 | $-0.01 | $4.55 | x |
| 2006-09-30 | $0.00 | $4.55 | x |
| 2007-09-30 | $-0.10 | $4.55 | x |
| 2008-09-30 | $-0.47 | $4.55 | x |
| 2009-09-30 | $-0.76 | $4.55 | x |
| 2010-09-30 | $-0.55 | $4.55 | x |
| 2011-09-30 | $-0.18 | $4.55 | x |
| 2012-09-30 | $-0.41 | $4.55 | x |
| 2013-09-30 | $-0.31 | $4.55 | x |
| 2014-09-30 | $0.02 | $4.55 | x |
| 2015-09-30 | $0.69 | $4.55 | x |
| 2016-09-30 | $0.18 | $4.55 | x |
| 2017-09-30 | $0.59 | $4.55 | x |
| 2018-09-30 | $0.46 | $4.55 | x |
| 2019-09-30 | $0.41 | $4.55 | x |
| 2020-09-30 | $0.47 | $4.55 | x |
| 2021-09-30 | $2.16 | $4.55 | x |
| 2022-09-30 | $1.85 | $4.55 | x |
| 2023-09-30 | $1.78 | $4.55 | x |
| 2024-09-30 | $1.44 | $4.55 | x |
| 2025-09-30 | $1.11 | $4.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anavex Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-48.89%) is above the historical average (-310.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -56.22% | 0.00% | 0.00x | 1.10x | $-16.96K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-89.02K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.98K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.53 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.12 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.11 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.49 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.19 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.01 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.45 Million |
| 2014 | -5901.77% | 0.00% | 0.00x | 38.18x | $-11.39 Million |
| 2015 | -94.53% | 0.00% | 0.00x | 1.21x | $-13.39 Million |
| 2016 | -233.61% | 0.00% | 0.00x | 1.51x | $-15.37 Million |
| 2017 | -55.50% | 0.00% | 0.00x | 1.15x | $-15.89 Million |
| 2018 | -85.17% | 0.00% | 0.00x | 1.19x | $-19.50 Million |
| 2019 | -129.60% | 0.00% | -0.03x | 1.25x | $-28.32 Million |
| 2020 | -96.49% | 0.00% | 0.00x | 1.27x | $-29.00 Million |
| 2021 | -25.14% | 0.00% | 0.00x | 1.07x | $-52.99 Million |
| 2022 | -33.67% | 0.00% | 0.00x | 1.07x | $-62.23 Million |
| 2023 | -33.48% | 0.00% | 0.00x | 1.09x | $-61.68 Million |
| 2024 | -35.76% | 0.00% | 0.00x | 1.13x | $-55.03 Million |
| 2025 | -48.89% | 0.00% | 0.00x | 1.09x | $-55.86 Million |
Industry Comparison
This section compares Anavex Life Sciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anavex Life Sciences Corp (AVXL) | $126.62 Million | -56.22% | 0.05x | $408.51 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |